| Literature DB >> 32246266 |
N H M Kooistra1, M Abawi1, M Voskuil2, K Urgel1, M Samim1,3, F Nijhoff1, H M Nathoe1, P A F M Doevendans1,4, S A J Chamuleau1, G E H Leenders1, T Leiner5, A C Abrahams6, H B van der Worp7, P Agostoni1,3, P R Stella1.
Abstract
INTRODUCTION: Transcatheter aortic valve implantation (TAVI) is a safe and effective treatment for inoperable, intermediate- or high-risk patients with severe symptomatic aortic stenosis and has been associated with excellent clinical outcomes. A clinically relevant remaining problem is aortic regurgitation (AR) post-TAVI, which is associated with increased mortality. Therefore, we conducted a prospective randomised trial to assess the safety and efficacy of a first-generation self-expandable valve (SEV; CoreValve) and a third-generation balloon-expandable valve (BEV; Sapien 3) with respect to clinical outcomes and AR as determined quantitatively by magnetic resonance imaging (MRI).Entities:
Keywords: Aortic valve stenosis; Balloon-expandable heart valve; Magnetic resonance imaging; Quantitative aortic regurgitation; Self-expandable heart valve; Transcatheter aortic valve implantation
Year: 2020 PMID: 32246266 DOI: 10.1007/s12471-020-01414-0
Source DB: PubMed Journal: Neth Heart J ISSN: 1568-5888 Impact factor: 2.380